Cited by 477HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Shattuck, David L., Miller, Jamie K., Carraway, Kermit L., Sweeney, Colleen·2008·Cancer Research

Open this paper in CoChat — free account

Abstract

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-5962

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

Show all 43 references

Sorted by citations

Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T. T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 636
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
Breast Cancer: Current Perspectives on the Disease Status
Ullah, M. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_4 · Cited by 601
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 523
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 516
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 553
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 465
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0797-x · Cited by 398
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 377
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P., Horowitz, I., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
Jung, E., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Leo, A. D., Le, X., Bast, R. C., Park, S., et al. (2011) · Cancer · doi:10.1002/cncr.26565 · Cited by 301
Towards personalized treatment for early stage HER2-positive breast cancer
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., Angelis, C. D., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0299-9 · Cited by 285
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 274
Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics
Gajbhiye, K. R., Salve, R., Narwade, M., Sheikh, A., Kesharwani, P., & Gajbhiye, V. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01849-0 · Cited by 276
Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X.-H., Esteva, F. J., & Liu, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3321 · Cited by 252
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258
Trastuzumab-Induced HER Reprogramming in “Resistant” Breast Carcinoma Cells
Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., & Maihle, N. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1056 · Cited by 243
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 234
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
Cruz, E., & Kayser, V. (2019) · Biologics · doi:10.2147/btt.s166310 · Cited by 245
Crosstalk in Met receptor oncogenesis
Lai, A. Z., Abella, J. V., & Park, M. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.07.002 · Cited by 220
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
Hojjat‐Farsangi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813768 · Cited by 208
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
Gagliato, D. D. M., Jardim, D. L. F., Marchesi, M., & Hortobágyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 204
The clinical and functional significance of c-Met in breast cancer: a review
Ho-Yen, C., Jones, J. L., & Kermorgant, S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0547-6 · Cited by 197
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Li, G., Guo, J., Shen, B., Yadav, D. B., Sliwkowski, M. X., Crocker, L., Lacap, J. A., & Phillips, G. D. L. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0296 · Cited by 200
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Wang, D., Liu, Z., Lu, Y., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316522 · Cited by 196
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Liu, Z., Duan, J., Song, Y., Ma, J., Wang, F., Lu, X., & Yang, X. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-148 · Cited by 194
HER2-directed therapy: current treatment options for HER2-positive breast cancer
Ahmed, S., Sami, A., & Xiang, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0587-x · Cited by 191
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
Nagatsuma, A. K., Aizawa, M., Kuwata, T., Doi, T., Ohtsu, A., Fujii, H., & Ochiai, A. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0360-4 · Cited by 182
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J. M., & Piccart, M. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 184
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2 -Amplified Gastric Cancer Cells
Chen, C., Kim, H., Liska, D., Gao, S. P., Christensen, J. G., & Weiser, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0754 · Cited by 179
Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
Luque-Cabal, M., García‐Teijido, P., Fernández-Pérez, Y., Sánchez‐Lorenzo, L., & Vázquez, I. P. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34537 · Cited by 186
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 188
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176
Pertuzumab: new hope for patients with HER2-positive breast cancer
Capelán, M., Pugliano, L., de Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C. P., Loi, S., & Piccart, M. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 174
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y.-C., Shou, J., Bissell, M. J., Osborne, C. K., & Schiff, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2936 · Cited by 165
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., Placido, S. D., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 169
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N. A., Roxanis, I., Li, J., Bridge, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1148 · Cited by 164
Management of breast cancer with targeted agents: importance of heterogenicity
Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159
Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling
Eterno, V., Zambelli, A., Pavesi, L., Villani, L., Zanini, V., Petrolo, G., Manera, S., Tuscano, A., & Amato, A. M. (2013) · Oncotarget · doi:10.18632/oncotarget.1359 · Cited by 161
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
García-García, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzmán, M., Grueso, J., Aura, C. M., Pérez-García, J. M., Jessen, K., Liu, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2750 · Cited by 158
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Patel, A., Unni, N. G., & Peng, Y. S. (2020) · Cancers · doi:10.3390/cancers12082081 · Cited by 147
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 142
Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges
Stern, H. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3001539 · Cited by 137
Current technologies for HER2 testing in breast cancer
Moelans, C. B., de Weger, R. A., van der Wall, E., & van Diest, P. J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.12.005 · Cited by 132
Multidrug-resistant breast cancer: current perspectives
Tomlinson, D. C., Martin, H. L., & Smith, L. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s37638 · Cited by 139
cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
Raghav, K. P. S., Wang, W., Liu, S., Chávez‐MacGregor, M., Meng, X., Hortobágyi, G. N., Mills, G. B., Meric‐Bernstam, F., Blumenschein, G. R., & Gonzalez-Angulo, A. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2830 · Cited by 131
Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Karagonlar, Z. F., Koç, D., İşcan, E., Erdal, E., & Atabey, N. (2016) · Cancer Science · doi:10.1111/cas.12891 · Cited by 132
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Karamouzis, M. V., Konstantinopoulos, P. A., & Papavassiliou, A. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70137-8 · Cited by 126
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 125
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000038508 · Cited by 139
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 119
Head neck squamous cell carcinoma c‐Met+ cells display cancer stem cell properties and are responsible for cisplatin‐resistance and metastasis
Sun, S., & Wang, Z. (2011) · International Journal of Cancer · doi:10.1002/ijc.25927 · Cited by 125
Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis
Ruprecht, B., Zaal, E. A., Zecha, J., Wu, W., Berkers, C. R., Küster, B., & Lemeer, S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2976 · Cited by 117
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Paul, M. D., & Hristova, K. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00467 · Cited by 122
Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation
Sun, C., Liu, Z., Li, S., Yang, C., Xue, R., Xi, Y., Wang, L., Wang, S., He, Q., Huang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4575 · Cited by 117
HGF-independent potentiation of EGFR action by c-Met
Dulak, A. M., Gubish, C. T., Stabile, L. P., Henry, C., & Siegfried, J. M. (2011) · Oncogene · doi:10.1038/onc.2011.84 · Cited by 115
Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met
Sun, C., Sang, M., Li, S., Sun, X., Yang, C., Xi, Y., Wang, L., Zhang, F., Bi, Y., Fu, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5476 · Cited by 116
Retracted
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 113
Trastuzumab
Garnock-Jones, K. P., Keating, G. M., & Scott, L. J. (2010) · Drugs · doi:10.2165/11203700-000000000-00000 · Cited by 114
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
Raina, D. B., Uchida, Y., Kharbanda, A., Rajabi, H. N., Panchamoorthy, G., Jin, C., Kharbanda, S. M., Scaltriti, M., Baselga, J. M., & Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2013.308 · Cited by 108
Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways
Ménard, L., Parker, P. J., & Kermorgant, S. (2014) · Nature Communications · doi:10.1038/ncomms4907 · Cited by 104
Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer
Wang, Y., Zhao, C., Chang, L., Jia, R., Liu, R., Zhang, Y., Gao, X., Li, J., Chen, R., Xia, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.003 · Cited by 101
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Fernández‐Nogueira, P., Mancino, M., Fuster, G., López‐Plana, A., Jáuregui, P., Almendro, V., Enreig, E., Menéndez, S., Rojo, F., Noguera‐Castells, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0353 · Cited by 104
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
Toschi, L., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0071 · Cited by 104
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Thomas, V. A., & Balthasar, J. P. (2019) · Antibodies · doi:10.3390/antib8040056 · Cited by 106
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 99
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer
Kim, Y. J., Choi, J., Seo, J., Song, J., Lee, S. E., Kwon, M. J., Kwon, M. J., Kundu, J., Jung, K., Oh, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28566 · Cited by 97
MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells
Fessler, S. P., Wotkowicz, M. T., Mahanta, S. K., & Bamdad, C. C. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0412-3 · Cited by 96
Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Schoeberl, B., & Sorger, P. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004379 · Cited by 93
Profile of neratinib and its potential in the treatment of breast cancer
Kong, A. H., & Feldinger, K. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s54414 · Cited by 99
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
Agarwal, S., Zerillo, C. A., Kolmakova, J., Christensen, J. G., Harris, L. N., Rimm, D. L., DiGiovanna, M. P., & Stern, D. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604937 · Cited by 92
Angiotensin-(1-7) Reduces Fibrosis in Orthotopic Breast Tumors
Cook, K. L., Metheny‐Barlow, L. J., Tallant, E. A., & Gallagher, P. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1136 · Cited by 92
Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Corso, S., & Giordano, S. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0040 · Cited by 96
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Stanley, A., Ashrafi, G. H., Seddon, A. M., & Modjtahedi, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04301-8 · Cited by 89
Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer
Sheikh, A., Md, S., & Kesharwani, P. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112530 · Cited by 90
β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer
Lesniak, D. M., Xu, Y., Deschênes, J., Lai, R. L., Thoms, J., Murray, D., Gosh, S., Mackey, J. R., Sabri, S., & Abdulkarim, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1591 · Cited by 91
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Nahta, R. (2012) · ISRN Oncology · doi:10.5402/2012/428062 · Cited by 93
c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Viticchiè, G., & Muller, P. A. J. (2015) · Biomedicines · doi:10.3390/biomedicines3010046 · Cited by 88
HER2 as a target for breast cancer therapy
Tagliabue, E., Balsari, A., Campiglio, M., & Pupa, S. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003689972 · Cited by 87
HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer
Sukawa, Y., Yamamoto, H., Nosho, K., Ito, M., Igarashi, H., Naito, T., Mitsuhashi, K., Matsunaga, Y., Takahashi, T., Mikami, M., et al. (2014) · Digestion · doi:10.1159/000356201 · Cited by 85
EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance
Dua, R., Zhang, J., Nhonthachit, P., Penuel, E. M., Petropoulos, C., & Parry, G. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0592-x · Cited by 90
Current challenges of metastatic breast cancer
Lim, B., & Hortobágyi, G. N. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9636-y · Cited by 87
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Lavaud, P., & André, F. (2014) · BMC Medicine · doi:10.1186/s12916-014-0132-3 · Cited by 82
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
Henjes, F., Bender, C., von der Heyde, S., Braun, L., Mannsperger, H., Schmidt, C., Wiemann, S., Hasmann, M., Aulmann, S., Beißbarth, T., et al. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.16 · Cited by 82
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
Rexer, B. N., Engelman, J. A., & Arteaga, C. L. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7324 · Cited by 84
Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling
Furlan, A., Colombo, F., Kövér, A., Issaly, N., Tintori, C., Angeli, L., Leroux, V., Letard, S., Amat, M., Asses, Y., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.051 · Cited by 86
HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
Kubota, T., Kuroda, S., Kanaya, N., Morihiro, T., Aoyama, K., Kakiuchi, Y., Kikuchi, S., Nishizaki, M., Kagawa, S., Tazawa, H., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.05.019 · Cited by 82

Authors: Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C.
Affiliations: UC Davis Comprehensive Cancer Center (US)
ORCID: Carraway, Kermit L.
Sweeney, Colleen
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-03-01
Volume: 68
Issue: 5
Pages: 1471-1477
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-07-5962
OpenAlex: W2027684043
Cited by: 473
References: 43
Citations by year: 2026: 6 · 2025: 18 · 2024: 12 · 2023: 30 · 2022: 18 · 2021: 22 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 24 · 2016: 26 · 2015: 33 · 2014: 37 · 2013: 41 · 2012: 42
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA123541, R01CA118384, R01CA123541, CA118384)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: MET receptor tyrosine kinase, trastuzumab resistance, HER2-positive breast cancer, combination therapy, MET inhibition, HER2-targeted therapy, drug resistance
MeSH terms: Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Breast, Breast Neoplasms, Humans, Models, Biological, Phosphorylation, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks